SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

2/13/23 11:33:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VNDA alert in real time by email

SC 13G/A 1 vnda-13g_20221231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VANDA PHARMACEUTICALS INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share ---------------------------------------------------------------------------- (Title of Class of Securities) 921659108 ---------------------------------------------------------------------------- (CUSIP Number) December 30, 2022 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 921659108 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 2,889,425 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 2,889,425 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,889,425 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.09 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. 921659108 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 2,889,425 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 2,889,425 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,889,425 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.09 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 921659108 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer VANDA PHARMACEUTICALS INC. (b) Address of Issuer's Principal Executive Offices. 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037 Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Common Stock, par value $0.001 per share (e) CUSIP Number. 921659108 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 2,889,425 shares RTHC: 2,889,425 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 5.09 % RTHC: 5.09 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 2,889,425 RTHC: 2,889,425 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 2,889,425 RTHC: 2,889,425 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [_] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2023 Renaissance Technologies LLC By: /s/ Brian Felczak Co-Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share of VANDA PHARMACEUTICALS INC. Date: February 13, 2023 Renaissance Technologies LLC By: /s/ Brian Felczak Co-Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Page 8 of 8 Pages

Get the next $VNDA alert in real time by email

Date

Price Target

Rating

Analyst

3/5/2026

$18.00

Buy

Truist

11/5/2025

$11.00

Buy

B. Riley Securities

10/31/2024

$18.00

Buy

H.C. Wainwright

7/11/2024

$11.00

Overweight

Cantor Fitzgerald

2/25/2022

$24.00 → $12.00

Buy → Hold

Jefferies

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

2/13/23 11:33:53 AM ET

$VNDA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VNDA alert in real time by email

Date

Price Target

Rating

Analyst

3/5/2026

$18.00

Buy

Truist

11/5/2025

$11.00

Buy

B. Riley Securities

10/31/2024

$18.00

Buy

H.C. Wainwright

7/11/2024

$11.00

Overweight

Cantor Fitzgerald

2/25/2022

$24.00 → $12.00

Buy → Hold

Jefferies

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $VNDA

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $VNDA

$VNDA Press Releases

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

$VNDA FDA approvals

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for FANAPT issued to VANDA PHARMS INC

$VNDA Insider Trading

Director Mitchell Stephen Ray gifted 25,836 shares, decreasing direct ownership by 27% to 71,246 units (SEC Form 4)

Director Duncan Charles Cliff was granted 57,101 shares (SEC Form 4)

SEC Form 3 filed by new insider Duncan Charles Cliff

$VNDA Insider Purchases

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

$VNDA SEC Filings

SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.

SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$VNDA Analyst Ratings

Truist initiated coverage on Vanda Pharma with a new price target

B. Riley Securities initiated coverage on Vanda Pharma with a new price target

H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

$VNDA Leadership Updates

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

$VNDA Financials

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

$VNDA Large Ownership Changes